New Light Shed on the Cause of Chronic Fatigue Syndrome
|
By LabMedica International staff writers Posted on 27 May 2015 |

Image: The MassARRAY mass spectrometer (Photo courtesy of Agena Bioscience).
The transient receptor potential (TRP) superfamily in humans comprises 27 cation channels with permeability to monovalent and divalent cations and these channels are widely expressed within humans on cells and tissues and have significant sensory and regulatory roles on most physiological functions.
Chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) is a highly debilitating disorder characterized by profound fatigue, muscle and joint pain, cerebral symptoms of impaired memory and concentration, impaired cardiovascular function, gut disorder and sensory dysfunction such as noise intolerance and balance disturbance.
Scientists at Griffith University (Gold Coast, QLD, Australia) and their colleagues recruited 115 CFS patients and 90 non-fatigued controls. Of the115 CFS patients (mean age: 48.7 ± 1.1 years), 84 (73.04%) were women and 31 (26.96%) were men. The 90 non-fatigued controls (mean age: 46.5 ± 1.2 years) comprised 59 (65.56%) women and 31 (34.44%) men. Ten milliliters of whole blood samples were collected from all participants in to ethylenediaminetetraacetic acid tubes.
Genomic DNA was extracted from all whole blood samples using the Qiagen DNA blood mini-kit (Qiagen; Venlo, Netherlands). The Nanodrop (Nanodrop; Wilmington, DE, USA) was used to assess the quality and quantity of the DNA extracted. Approximately 2 μg of genomic DNA was used in the single nuclear polymorphisms (SNP) assay. SNP analysis was performed using the MassARRAY iPLEX Gold Assay and following the iPLEX Gold reaction, MassARRAY was performed using the MassARRAY mass spectrometer, (Agena Bioscience; San Diego, CA, USA).
Of the 240 SNPs that were examined in the study, 233 were successfully identified in both participants groups and 13 were observed to be significantly associated with CFS. Nine of these SNPs were associated with transient receptor potential melostatin (TRPM3) while the remaining SNPs were associated with TRPA1 (ankyrin) and TRPC4 (canonical).
Pete Smith, MBBS, FRACP, PhD, a professor of immunology and a coauthor of the study said, “Important signaling mechanisms are disrupted as a result of these genetic changes involving the detection and response to threats. These are primitive genes that are involved in many cellular signals in the brain, gut, cardiovascular and immune systems, as well as in the mediation of pain.” The study was published on May 10, 2015, in the journal Immunology and Immunogenetics Insights.
Related Links:
Griffith University
Qiagen
Agena Bioscience
Chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) is a highly debilitating disorder characterized by profound fatigue, muscle and joint pain, cerebral symptoms of impaired memory and concentration, impaired cardiovascular function, gut disorder and sensory dysfunction such as noise intolerance and balance disturbance.
Scientists at Griffith University (Gold Coast, QLD, Australia) and their colleagues recruited 115 CFS patients and 90 non-fatigued controls. Of the115 CFS patients (mean age: 48.7 ± 1.1 years), 84 (73.04%) were women and 31 (26.96%) were men. The 90 non-fatigued controls (mean age: 46.5 ± 1.2 years) comprised 59 (65.56%) women and 31 (34.44%) men. Ten milliliters of whole blood samples were collected from all participants in to ethylenediaminetetraacetic acid tubes.
Genomic DNA was extracted from all whole blood samples using the Qiagen DNA blood mini-kit (Qiagen; Venlo, Netherlands). The Nanodrop (Nanodrop; Wilmington, DE, USA) was used to assess the quality and quantity of the DNA extracted. Approximately 2 μg of genomic DNA was used in the single nuclear polymorphisms (SNP) assay. SNP analysis was performed using the MassARRAY iPLEX Gold Assay and following the iPLEX Gold reaction, MassARRAY was performed using the MassARRAY mass spectrometer, (Agena Bioscience; San Diego, CA, USA).
Of the 240 SNPs that were examined in the study, 233 were successfully identified in both participants groups and 13 were observed to be significantly associated with CFS. Nine of these SNPs were associated with transient receptor potential melostatin (TRPM3) while the remaining SNPs were associated with TRPA1 (ankyrin) and TRPC4 (canonical).
Pete Smith, MBBS, FRACP, PhD, a professor of immunology and a coauthor of the study said, “Important signaling mechanisms are disrupted as a result of these genetic changes involving the detection and response to threats. These are primitive genes that are involved in many cellular signals in the brain, gut, cardiovascular and immune systems, as well as in the mediation of pain.” The study was published on May 10, 2015, in the journal Immunology and Immunogenetics Insights.
Related Links:
Griffith University
Qiagen
Agena Bioscience
Latest Molecular Diagnostics News
- Blood Test Maps Tumor Microenvironment to Predict Immunotherapy Response
- Multiplex Respiratory Panel Integrates Automated Extraction to Streamline High-Volume Testing
- Whole-Blood RNA Test Predicts Disease Trajectory and Treatment Response
- Blood-Based Epigenetic Test Predicts GLP-1 Response and Tracks Treatment Effects
- Tumor Genomic Testing Guides Immunotherapy Selection in Pituitary Tumors
- Liquid Biopsy Predicts Immunotherapy Response in Breast Cancer
- New Blood Test Distinguishes Pancreatic Cancer From Benign Disease
- Noninvasive Test Confirms High-Risk Prenatal Screening Results from Blood
- Machine-Learning Genetic Risk Score Improves Early Prediction of Type 1 Diabetes
- Rapid Tongue Swab Molecular Test Detects Pulmonary Tuberculosis at Point of Care
- CRISPR-Based Test Identifies Multiple Respiratory Viruses Simultaneously
- Blood Test Receives FDA Breakthrough Status to Differentiate Schizophrenia and Bipolar Disorder
- Portable Test Detects Tuberculosis from Tongue Swabs in 30 Minutes
- Multi-Omic Assay Predicts Recurrence and Radiation Benefit in Early Breast Cancer
- Genomic Risk Score Identifies Inherited Risk for Multiple Cardiovascular Conditions
- Genomic Classifiers Improve Risk Stratification and Treatment Selection in Urologic Cancers
Channels
Clinical Chemistry
view channel
Ultrasensitive Test Detects Key Biomarker of Frontotemporal Dementia Subtype
Dementia affects more than 57 million people worldwide and is projected to nearly double within two decades, straining health systems and families. While biomarkers now enable accurate identification of... Read more
Routine Blood Tests Years Before Pregnancy Could Identify Preeclampsia Risk
High blood pressure during pregnancy is common and can progress to pre-eclampsia, making close monitoring at antenatal visits essential. However, most risk assessment begins only after pregnancy has started.... Read moreMolecular Diagnostics
view channel
Blood Test Maps Tumor Microenvironment to Predict Immunotherapy Response
Immunotherapy has transformed cancer care, yet durable benefit remains limited to a subset of patients, and clinicians still lack reliable tools to predict response before treatment begins.... Read more
Multiplex Respiratory Panel Integrates Automated Extraction to Streamline High-Volume Testing
Respiratory infections drive heavy testing volumes in clinical laboratories, where accurate, timely results across multiple pathogens are essential. Many labs are seeking to streamline workflows and increase... Read more
Whole-Blood RNA Test Predicts Disease Trajectory and Treatment Response
Clinicians often must predict whether acutely ill patients will recover or deteriorate despite limited time and clinical evidence. Earlier prognostic information could improve triage and guide treatment... Read more
Blood-Based Epigenetic Test Predicts GLP-1 Response and Tracks Treatment Effects
Prescriptions for GLP-1 medicines for weight loss are expanding rapidly, yet clinicians still lack scalable tools to predict biological response before treatment or monitor drug-driven changes beyond the scale.... Read moreHematology
view channel
Advanced CBC-Derived Indices Integrated into Hematology Platforms
Diatron, a STRATEC brand, has introduced six advanced hematological indices on its Aquila, Aquarius 3, and Abacus 5 hematology analyzers. The new Research Use Only (RUO) indices include Neutrophil-to-Lymphocyte... Read more
Blood Test Enables Early Detection of Multiple Myeloma Relapse
Bone marrow biopsies remain central to diagnosing and monitoring multiple myeloma, yet the procedure is painful, invasive, and often repeated over time. Older patients—who represent most new cases—can... Read moreMicrobiology
view channel
Rapid Antigen Biosensor Detects Active Tuberculosis in One Hour
Tuberculosis remains a major global health challenge and continues to drive significant morbidity and mortality. The World Health Organization’s 2024 global report cites it as the leading cause of death... Read more
Oral–Gut Microbiome Signatures Identify Early Gastric Cancer
Early detection of gastric cancer could be advanced by scalable screening strategies using minimally invasive sampling. Saliva collection is noninvasive and cost-effective, supporting wider adoption... Read morePathology
view channel
FDA Clears AI Digital Pathology Tool for Breast Cancer Risk Stratification
Risk assessment at diagnosis is central to guiding therapy for early-stage, hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) invasive breast cancer, where overtreatment... Read more
New AI Tool Reveals Hidden Genetic Signals in Routine H&E Slides
Pathologists worldwide rely on hematoxylin and eosin (H&E) slides to examine tissue architecture, yet these stains do not reveal the underlying molecular activity that often drives disease.... Read moreTechnology
view channel
Tumor-on-a-Chip Platform Models Pancreatic Cancer Treatment Response
Pancreatic cancer remains one of the hardest malignancies to treat because tumors are embedded within a dense microenvironment that shapes growth and therapy response. Standard laboratory models often... Read more
New Platform Captures Extracellular Vesicles for Early Cancer Detection
Early diagnosis remains the most effective way to reduce cancer mortality, yet many screening tools miss disease at its earliest stages. Biomarkers shed by tumors into blood and other fluids can be scarce... Read moreIndustry
view channel








